Literature DB >> 11405614

C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging.

I Kushner1.   

Abstract

Epidemiologic studies have revealed that minimal acute-phase changes predict poor prognoses in many conditions and predict disability and mortality in the elderly. These findings have usually been interpreted to indicate that inflammatory processes of some kind play a role in these situations. In fact, a minimal acute-phase response does not necessarily establish the existence of an inflammatory process but may also reflect a variety of noninflammatory states, including obesity, sleep disturbance, depression, chronic fatigue, and low levels of physical activity. I propose that a minimal acute-phase response may also be a marker of biologic aging, a condition known to predispose to poor prognoses and to death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405614     DOI: 10.3949/ccjm.68.6.535

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  10 in total

Review 1.  Oxidative stress and inflammation in brain aging: nutritional considerations.

Authors:  J A Joseph; B Shukitt-Hale; G Casadesus; D Fisher
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

2.  C-reactive protein levels in patients on maintenance hemodialysis: reliability and reflection on the utility of single measurements.

Authors:  Caroline E Stigant; Ognjenka Djurdjev; Adeera Levin
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia.

Authors:  Junshik Hong; Hyun Seon Woo; Hee Kyung Ahn; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Support Care Cancer       Date:  2015-05-19       Impact factor: 3.603

Review 4.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

5.  Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study.

Authors:  David E Chiriboga; Yunsheng Ma; Wenjun Li; Edward J Stanek; James R Hébert; Philip A Merriam; Eric S Rawson; Ira S Ockene
Journal:  Clin Chem       Date:  2009-02       Impact factor: 8.327

6.  Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood.

Authors:  Najib Aziz; John L Fahey; Roger Detels; Anthony W Butch
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 7.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

Review 8.  Biomarkers in community-acquired pneumonia: a state-of-the-art review.

Authors:  Renato Seligman; Luis Francisco Ramos-Lima; Vivian do Amaral Oliveira; Carina Sanvicente; Elyara F Pacheco; Karoline Dalla Rosa
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

9.  C-Reactive Protein Impairs Dendritic Cell Development, Maturation, and Function: Implications for Peripheral Tolerance.

Authors:  Rachel V Jimenez; Tyler T Wright; Nicholas R Jones; Jianming Wu; Andrew W Gibson; Alexander J Szalai
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

10.  Inflammatory Biomarkers and Breast Cancer Risk: A Systematic Review of the Evidence and Future Potential for Intervention Research.

Authors:  Rebecca D Kehm; Jasmine A McDonald; Suzanne E Fenton; Marion Kavanaugh-Lynch; Karling Alice Leung; Katherine E McKenzie; Jeanne S Mandelblatt; Mary Beth Terry
Journal:  Int J Environ Res Public Health       Date:  2020-07-28       Impact factor: 4.614

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.